Alteplase: Low dose for Intermediate/High risk PE

Who can administer

Administration restricted- see Appendix 1 below

Important information

  • Unlicensed indication
  • Patients MUST be discussed with some or all of the following:
    • Consultant Anaesthetist/Intensivist
    • Consultant Respiratory physician
    • Consultant Haematologist
    • Consultant Radiologist
    • Consultant Cardiologist
  • Consider in patient with acute PE where there is clinical concern AND
    • Evidence of right heart strain (increased troponin+/- increased pro-BNP) and/or RV dilatation on echo
    • Patients not improving on anticoagulation or worsening of biomarkers/RV strain despite anticoagulation
    • Patient not a candidate for full dose (100mg) alteplase due to concerns regarding bleeding or who do not meet criteria for 100mg dose for acute massive pulmonary embolism with haemodynamic instability
    • For use in thrombolysis (acute MI), acute massive PE, acute ischaemic stroke - see separate monograph

    • For use in Catheter-directed Thrombolysis- see separate monograph

    Available preparations

    • Actilyse 10mg vial (with 10ml Water for Injection provided)


    • Use 10ml Water for Injection provided

    Infusion fluids

    Sodium chloride 0.9% only

    Dilution Concentration produced
    10mg added to 40ml infusion fluid to produce a final volume of 50ml 1mg per 5ml

    The product must only be diluted and reconstituted as outlined here, due to stability issues at other concentrations  (SPC)

    Methods of intravenous administration

    Bolus intravenous injection (ref 1)

    • Administer required dose over 1 to 2 minutes 

    Intermittent intravenous infusion (administer using an electronically controlled infusion device)

    • Administer required dose as per Dose below
    • May be administered via a peripheral cannula in the Critical care setting
    • Syringe must be changed after 8 hours (no stability data beyond 8 hours at room temperature)

    Dose in adults

    Pulmonary embolism (Low dose for Intermediate/High risk PE)(for patients meeting criteria in Important information above)

    • Administer 10mg as a bolus intravenous injection
    • Follow bolus injection with an infusion of 1mg/hour (5ml/hour) for 24 hours or until clinical improvement
    • Concomitant heparin administration is required (either UFH or LMWH depending on patient's clinical condition)

    For doses in other indications see separate monographs


    • Baseline: Check PT, aPTT, FBC, Clauss fibrinogen, troponin, pro-BNP
    • Recheck Coag including Clauss fibrinogen 8 hourly (depending on heparin regimen) or if bleeding
    • Risk of bleeding is lower with this regimen than the full dose alteplase regimen
    • Ensure Clauss fibrinogen is greater than 1.0g/L


    • Store below 250C
    • Syringe must be changed after 8 hours (no stability data beyond 8 hours at room temperature)


    1: Injectable Medicines Administration guide (downloaded from Medusa 21st April 2021)

    Locally produced guidelines:  approved by Dr. Ruth Gilmore (Haematologist). 29 July 2021.

    Therapeutic classification

    • Fibrinolytic agent